The Effects of the Dietary Supplement CardioFlex Q10 on Reducing Cardiovascular Disease Risk Factors in Adults
Condition: Cardiovascular Diseases; Cardiovascular Abnormalities; Heart Attack; Stroke; Hypertension
MeSH terms: Hypertension; Cardiovascular Diseases; Myocardial Infarction; Cardiovascular Abnormalities
Study type: Interventional

Summary: 
      Cardiovascular diseases (CVD), primarily heart disease and stroke, are the leading causes of
      death and prescription drug use in Canada. Research on certain dietary supplements looks
      promising as a way to help reduce CVD risk factors. Studies show that supplementation of
      certain nutrients such as antioxidants, amino acids, electrolytes, vitamins and minerals may
      effectively reduce cardiovascular risk factors. The dietary supplement CardioFlex Q10, which
      is high in the aforementioned components, was developed to help regulate the body's
      production of cholesterol, strengthen the arteries and heart, and reverse oxidation.

      The overall objective of this study is to determine if 90 days of supplementing with
      CardioFlex Q10 can reduce CVD risk factors in adults, independent of other dietary or
      physical activity changes.
    

Detailed description: 
      The purpose of this study is to determine whether or not daily supplementation with the
      dietary supplement CardioFlex Q10 for 90 days can reduce cardiovascular risk factors in
      healthy adults. The health markers that will be tested include the participant's waist
      circumference, body weight, body mass index (BMI), atherosclerosis risk factors (blood
      pressure, plethysmogram (PTG) wave form, heart rate variability, accelerated plethysmograph
      (APG) type (biological age of arteries)), and blood work including total plasma lipid profile
      (total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL),
      triglycerides (TGs)), kidney and liver function (alanine aminotransferase (ALT), aspartate
      aminotransferase (AST), Lactate dehydrogenase (LDH), Blood Urea Nitrogen (BUN), creatinine),
      and inflammatory and endothelial function biomarkers (C-reactive protein (CRP), Interleukin-6
      (IL-6), soluble intercellular cell adhesion molecule-1 (sICAM-1), soluble vascular cell
      adhesion molecule-1 (sVCAM-1) ).

      All health markers will be tested the day before starting the study and the day after the
      study is completed.
    

Intervention name(s): CardioFlex Q10; Placebo
Intervention type(s): Dietary Supplement; Dietary Supplement
Intervention description(s): CardioFlex Q10 is a cardiovascular health supplement developed to increase collagen production, repair connective tissues, and help the body metabolize fats and protein. CardioFlex Q10 contains high amounts of lysine, proline and vitamin C, which the body requires to produce connective tissue (collagen). CardioFlex Q10 also includes additional supporting nutrients such as vitamin E, selenium, bio flavonoids, Coenzyme Q10 (Ubiqionol) and magnesium. The ingredients in CardioFlex Q10 help regulate the body's production of cholesterol, strengthen the arteries and heart, and reverse oxidation.; Isocaloric maltodextrin placebo that looks and tastes identical to CardioFLex Q10
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: A 90-day double blinded controlled clinical trial
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Prevention
Keywords: dietary supplements; cardiovascular diseases; heart attack; stroke; hypertension; amino acids; electrolytes; antioxidants